Evidence map›Paper›PMID 25383959›Full record

ArticlePloS one2014

Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis.

Xiaoxi Han, Shengkun Sun, Ming Zhao, Xiang Cheng, Guozhu Chen, Song Lin, Yifu Guan, Xiaodan Yu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Autophagy in the pharmacological activities of celastrol (Review).Experimental and therapeutic medicine · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiaoxi HanDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, China.
Shengkun SunDepartment of Urology, The General Hospital of PLA, Beijing, China.
Ming ZhaoDepartment of Cognitive Science, Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing, China.
Xiang ChengDepartment of Cognitive Science, Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing, China.
Guozhu ChenDepartment of Cognitive Science, Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing, China.
Song LinDepartment of Cognitive Science, Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing, China.
Yifu GuanDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, China.
Xiaodan YuDepartment of Cognitive Science, Institute of Basic Medical Sciences, Cognitive and Mental Health Research Center, Beijing, China.
Institute of Basic Medical Sciences of the Chinese Academy of Medical SciencesChina Medical University · CNThe Military General Hospital of Beijing PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Celastrol, a tripterine derived from the traditional Chinese medicine plant Tripterygium wilfordii Hook F. ("Thunder of God Vine"), has been reported to have multiple effects, such as anti-inflammation, suppression of tumor angiogenesis, inhibition of tumor growth, induction of apoptosis and protection of cells against human neurodegenerative diseases. However, the mechanisms that underlie these functions are not well defined. In this study, we reported for the first time that Celastrol could induce HIF-1α protein accumulation in multiple cancer cell lines in an oxygen-independent manner and that the enhanced HIF-1α protein entered the nucleus and promoted the transcription of the HIF-1 target genes VEGF and Glut-1. Celastrol did not influence HIF-1α transcription. Instead, Celastrol induced the accumulation of the HIF-1α protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1α translation. In addition, we found that the activation of Akt by Celastrol was transient. With increased exposure time, inhibition of Hsp90 chaperone function by Celastrol led to the subsequent depletion of the Akt protein and thus to the suppression of Akt activity. Moreover, in HepG2 cells, the accumulation of HIF-1α increased the expression of BNIP3, which induced autophagy. However, HIF-1α and BNIP3 did not influence the cytotoxicity of Celastrol because the main mechanism by which Celastrol kills cancer cells is through stimulating ROS-mediated JNK activation and inducing apoptosis. Furthermore, our data showed that the dose required for Celastrol to induce HIF-1α protein accumulation and enhance HIF-1α transcriptional activation was below its cytotoxic threshold. A cytotoxic dose of Celastrol for cancer cells did not display cytotoxicity in LO2 normal human liver cells, which indicated that the novel functions of Celastrol in regulating HIF-1 signaling and inducing autophagy might be used in new applications, such as in anti-inflammation and protection of cells against human neurodegenerative diseases. Future studies regarding these applications are required.

Indexed as

Cell LineCell NucleusGene Expression Regulation, NeoplasticGlucose Transporter Type 1HeLa CellsHep G2 CellsHumansHypoxia-Inducible Factor 1, alpha SubunitMCF-7 CellsNeoplasmsPentacyclic TriterpenesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSignal TransductionTriterpenesVascular Endothelial Growth Factor AcelastrolGlucose Transporter Type 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPentacyclic TriterpenesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSLC2A1 protein, humanTriterpenesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25383959
PMCPMC4226555
OpenAlexW2042927161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.